Analysts Expect Calyxt Inc (NASDAQ:CLXT) to Post -$0.33 Earnings Per Share

Share on StockTwits

Wall Street brokerages predict that Calyxt Inc (NASDAQ:CLXT) will announce ($0.33) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Calyxt’s earnings. Calyxt posted earnings per share of ($0.23) during the same quarter last year, which suggests a negative year-over-year growth rate of 43.5%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 5th.

On average, analysts expect that Calyxt will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.32). For the next year, analysts expect that the business will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.37) to ($1.36). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Calyxt.

Calyxt (NASDAQ:CLXT) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.04). Calyxt had a negative net margin of 543.00% and a negative return on equity of 52.37%. The firm had revenue of $3.76 million for the quarter.

A number of brokerages have weighed in on CLXT. Wells Fargo & Co downgraded shares of Calyxt from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $15.00 to $6.00 in a research note on Friday, March 6th. Jefferies Financial Group downgraded shares of Calyxt from a “buy” rating to a “hold” rating in a research note on Monday. National Securities reaffirmed a “buy” rating and issued a $16.00 target price on shares of Calyxt in a research note on Friday, March 6th. BidaskClub raised shares of Calyxt from a “hold” rating to a “buy” rating in a research note on Tuesday, January 7th. Finally, Goldman Sachs Group downgraded shares of Calyxt from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $19.00 to $7.00 in a research note on Thursday, March 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $9.90.

Shares of NASDAQ CLXT opened at $3.98 on Friday. Calyxt has a 1-year low of $2.40 and a 1-year high of $17.90. The company has a market cap of $120.41 million, a PE ratio of -3.29 and a beta of 2.02. The company has a current ratio of 8.83, a quick ratio of 8.47 and a debt-to-equity ratio of 0.29. The company has a 50-day moving average of $5.00 and a two-hundred day moving average of $5.53.

In other Calyxt news, Director Yves J. Ribeill sold 9,990 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $5.46, for a total value of $54,545.40. Following the completion of the transaction, the director now directly owns 38,320 shares of the company’s stock, valued at $209,227.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders acquired 750 shares of company stock valued at $5,200. Insiders own 2.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp grew its holdings in Calyxt by 7.7% during the third quarter. State Street Corp now owns 136,955 shares of the company’s stock valued at $772,000 after purchasing an additional 9,775 shares during the period. California Public Employees Retirement System grew its holdings in Calyxt by 7.8% during the third quarter. California Public Employees Retirement System now owns 94,401 shares of the company’s stock valued at $532,000 after purchasing an additional 6,801 shares during the period. Millennium Management LLC grew its holdings in Calyxt by 242.2% during the third quarter. Millennium Management LLC now owns 49,839 shares of the company’s stock valued at $281,000 after purchasing an additional 35,275 shares during the period. Barclays PLC grew its holdings in Calyxt by 97.3% during the fourth quarter. Barclays PLC now owns 9,421 shares of the company’s stock valued at $66,000 after purchasing an additional 4,646 shares during the period. Finally, Rhumbline Advisers acquired a new position in Calyxt during the fourth quarter valued at approximately $72,000. 24.46% of the stock is owned by institutional investors and hedge funds.

About Calyxt

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.

Read More: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Calyxt (CLXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nuveen Asset Management LLC Has $48.56 Million Stake in Discovery Communications Inc.
Nuveen Asset Management LLC Has $48.56 Million Stake in Discovery Communications Inc.
Norges Bank Makes New Investment in Charles River Laboratories Intl. Inc
Norges Bank Makes New Investment in Charles River Laboratories Intl. Inc
Macquarie Group Ltd. Has $9.21 Million Stock Position in HCA Healthcare Inc
Macquarie Group Ltd. Has $9.21 Million Stock Position in HCA Healthcare Inc
Cardiovascular Systems  Given New $54.00 Price Target at Lake Street Capital
Cardiovascular Systems Given New $54.00 Price Target at Lake Street Capital
Janus Henderson Group PLC Buys New Stake in Associated Banc Corp
Janus Henderson Group PLC Buys New Stake in Associated Banc Corp
Brunswick Co.  Shares Purchased by Nuveen Asset Management LLC
Brunswick Co. Shares Purchased by Nuveen Asset Management LLC


© 2006-2020 Ticker Report